(Press-News.org) CHICAGO -- ASCO Abstract #10504. Contrary to what many oncologists had thought, a tumor suppressor protein known as PTEN does not reduce the effectiveness of the breast cancer drug Herceptin, according to a study by Mayo Clinic and North Central Cancer Research Group (NCCTG) investigators. The study, which looked at tumors from 1,802 patients enrolled in the NCCTG N9831 clinical trial, found that patients with HER2-positive breast cancer and had either a loss of PTEN functioning or normal PTEN activity did equally well when Herceptin was added to chemotherapy to prevent breast cancer recurrence.
VIDEO ALERT: Additional audio and video resources are available at the Mayo Clinic News Blog. Password: perez
The researchers presented their findings during the American Society of Clinical Oncology Annual Meeting in Chicago.
"This is the largest study to date evaluating PTEN's presence or loss in the context of antiHER2 therapy, and we found no connection," says the study's lead investigator, oncologist Edith Perez, M.D., director of the Breast Clinic at Mayo Clinic in Jacksonville, Fla., and the Serene M. and Frances C. Durling Professor. "Our research team is very pleased to be able to test an important question in treatment of breast cancer and arrive at a definitive answer."
The researchers stained the samples for PTEN expression and linked that data with disease-free survival. They found that PTEN status did not impact disease-free survival significantly; there was only a slightly greater benefit of adding Herceptin for patients with PTEN-tumors.
Preclinical studies and some small patient studies had suggested that tumors with loss of PTEN expression would not benefit from Herceptin, Dr. Perez says. As a result, investigators were considering using PTEN biomarkers in clinical studies as a test of Herceptin resistance, and patients who tested positive for PTEN loss might then be offered other therapies, or invited to participate in clinical trials.
"We have all been interested in biomarkers that predict for benefit to antiHER2 therapy," Dr. Perez says, "but PTEN is not one that we should pursue further, based on our rigorous analysis."
The tumor samples examined in the study came from NCCTG N9831, a phase III randomized, multicenter clinical trial that tested adjuvant Herceptin given with, or following, chemotherapy with paclitaxel, compared with chemotherapy alone.
###
The study was funded by the National Cancer Institute, the National Institutes of Health and Genentech. The study includes 16 co-authors; nine are from the Mayo Clinic campuses in Florida, Minnesota, and Arizona.
Mayo Clinic, NCCTG find no tie between PTEN and response to breast cancer drug
2011-06-04
ELSE PRESS RELEASES FROM THIS DATE:
Combination antibody therapy shows promise in metastatic melanoma
2011-06-04
BOSTON--A duo of drugs, each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase 1 clinical trial led by Dana-Farber Cancer Institute investigators.
The findings (abstract 8511), will be presented in an oral session at the annual meeting of the American Society of Clinical Oncology on Saturday, June 4, 3 p.m. CT, Arie Crown Theater, McCormick Place.
The drugs -- ipilimumab and bevacizumab -- are both monoclonal antibodies, intensified ...
NASA watching 2 areas in the Caribbean, 1 is a rainmaker
2011-06-04
There are two low pressure areas in the Caribbean Sea for future development into tropical cyclones, although the chances are near zero for one, and minimal for the other. The GOES-13 satellite has been following the life of System 93L, which is one of those systems. The second low pressure area may not develop over the weekend, but threatens heavy rain in Hispaniola, Cuba and Jamaica.
The GOES-13 satellite provides images of the U.S. east coast, Atlantic and Caribbean Sea continually every day. In an image from 1731 UTC (1:31 p.m. EDT) today, June 3, the low pressure ...
Silberstein, Awad & Miklos Joins Environmental Alliance
2011-06-04
Silberstein, Awad & Miklos, P.C., is doing more to help New Yorkers by making a commitment to improve its environmental profile. The firm has long been the voice of those hurt by medical errors, but now it hopes to promote awareness of eco-friendly business practices for lawyers through the B2B Green Alliance.
The B2B Green Alliance is sponsored by web marketing firm Page 1 Solutions, part of Page 1 Green Solutions, an environmental commitment program. Page 1 Solutions strives to become a positive force for change not only by following eco-conscious practices in ...
Sheridan Dental Joins Environmental Alliance
2011-06-04
Sheridan Dental is making a commitment to clean up its Columbus, Ohio community by improving its environmental profile. Sheridan Dental seeks to do the best for its neighbors both in the chair and in the environment by promoting awareness of eco-friendly business practices for dentists through the B2B Green Alliance.
The B2B Green Alliance is one branch of Page 1 Green Solutions, an environmental commitment program sponsored by Page 1 Solutions. Page 1 Solutions has long made a professional commitment to eco-friendly practices in its office, but now hopes to expand ...
How muscle develops: A dance of cellular skeletons
2011-06-04
Revealing another part of the story of muscle development, Johns Hopkins researchers have shown how the cytoskeleton from one muscle cell builds finger-like projections that invade into another muscle cell's territory, eventually forcing the cells to combine.
Such muscle cell fusion, the researchers say, is not only important for understanding normal muscle growth, but also muscle regeneration after injury or disease. The work, they believe, could further development of therapies for muscular dystrophy or age-related muscle wasting.
Their report on muscle cell cytoskeletons, ...
Moral responses change as people age
2011-06-04
Moral responses change as people age says a new study from the University of Chicago.
Both preschool children and adults distinguish between damage done either intentionally or accidently when assessing whether a perpetrator has done something wrong, said study author Jean Decety. But, adults are much less likely than children to think someone should be punished for damaging an object, for example, especially if the action was accidental.
The study, which combined brain scanning, eye-tracking and behavioral measures to understand brain responses, was published in the ...
Understanding cancer energetics
2011-06-04
It's long been known that cancer cells eat a lot of sugar to stay alive. In fact, where normal, noncancerous cells generate energy from using some sugar and a lot of oxygen, cancerous cells use virtually no oxygen and a lot of sugar. Many genes have been implicated in this process and now, reporting in the May 27 issue of Cell, researchers at the Johns Hopkins University School of Medicine have discovered that this so-called Warburg effect is controlled.
"It turns out to be a feed-forward mechanism, where protein A turns on B, which in turn goes back and helps A do more," ...
Expungement of Criminal Records in Pennsylvania
2011-06-04
In criminal law, an expungement is the removal of all official records that can tie an individual to a given legal offense. Under certain limited circumstances, Pennsylvania residents with criminal records may file a petition for expungement. Of course, even though there are many advantages to having criminal records expunged, the wide availability of public information online often makes expungement an imperfect solution.
The Expungement Process
Only a few types of records are eligible for expungement in Pennsylvania. Records of non-convictions (such as not guilty ...
Could a birth control pill for men be on the horizon?
2011-06-04
(NEW YORK, NY, June 4, 2011) – Researchers at Columbia University Medical Center are honing in on the development of what may be the first non-steroidal, oral contraceptive for men. Tests of low doses of a compound that interferes with retinoic acid receptors (RARs), whose ligands are metabolites of dietary vitamin A, showed that it caused sterility in male mice.
Earlier results of the experiments using this RAR antagonist were published in the June 1st issue of Endocrinology, and an abstract extending the studies to longer drug delivery periods is scheduled for the Late ...
Fighting cancer with cancer: Mayo Clinic finds promising use for thyroid cancer gene
2011-06-04
ROCHESTER, Minn. -- A mutant gene long thought to accelerate tumor growth in thyroid cancer patients actually inhibits the spread of malignant cells, showing promise for novel cancer therapies, a Mayo Clinic study has found. The findings will be presented by Mayo Clinic researcher Honey Reddi, Ph.D., at the Endocrine Society meeting in Boston.
Dr. Reddi's discovery could have widespread implications in cancer research and endocrinology. It could help oncologists sharpen the diagnosis of specific types of thyroid cancers, while leading pharmaceutical researchers toward ...